Response to Miller et al: resistant mutations in CML and Ph(+) ALL – role of ponatinib
Nathalie Bardy-Bouxin, Ewa Matczak, Geeta Devgan, Mabel Woloj, Mark Shapiro Pfizer Oncology, Pfizer Inc., New York, NY, USAMiller et al1 recently reviewed the role of ponatinib in chronic myeloid leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL), y...
Guardado en:
| Autores principales: | , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2015
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/df7e828356464b2fad8d887cda21e1aa |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| Sumario: | Nathalie Bardy-Bouxin, Ewa Matczak, Geeta Devgan, Mabel Woloj, Mark Shapiro Pfizer Oncology, Pfizer Inc., New York, NY, USAMiller et al1 recently reviewed the role of ponatinib in chronic myeloid leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL), yet by the omission of an approved agent within the same class of drugs, provided an inaccurate summary of the current treatment landscape for CML. View original paper by Miller and colleagues. |
|---|